{"name":"Alector Inc.","slug":"alector-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AL001","genericName":"AL001","slug":"al001","indication":"Alzheimer's disease (early symptomatic or prodromal stage)","status":"phase_3"},{"name":"AL003","genericName":"AL003","slug":"al003","indication":"Alzheimer's disease","status":"marketed"}]}],"pipeline":[{"name":"AL001","genericName":"AL001","slug":"al001","phase":"phase_3","mechanism":"AL001 is a monoclonal antibody that activates TREM2 signaling on microglia to promote neuroinflammatory resolution and clearance of pathogenic proteins in neurodegenerative disease.","indications":["Alzheimer's disease (early symptomatic or prodromal stage)"],"catalyst":""},{"name":"AL003","genericName":"AL003","slug":"al003","phase":"marketed","mechanism":"AL003 is a monoclonal antibody that activates TREM2 signaling on microglia to promote neuroinflammatory resolution and clearance of pathogenic proteins in the central nervous system.","indications":["Alzheimer's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNZ01nVTRGNVp0VGRlSXZtdUd4dTEwV1gwUUpYMHN2WWFNMUlPT3gxc29TRmFzbF9DSnZJYU00RUJLdXJWTEJaYzFIaEw0LXpZRFhwaXgtdlJNUVEyWGNBV0ZTNGhnNlJZRHhPYTctMnhYTGF5amxWVGw0TjJTTlU5OXVfNG1uZ2FSb01iQjlkaFFnQ3p2eEFab0xqZ0UtUlhfc2pDa0kydFhzRXJiQkc4NXhxVEVCUQ?oc=5","date":"2026-04-01","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga","headline":"12 Health Care Stocks Moving In Wednesday's Intraday Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdEc1aktTZjRfbWNCTy1WNFJpMmFHX3ZVNmxxZVhVYlV0VVRLQl9Gb29fdjh5Z2NVWWs3dzNlZ0xaeS1TOU1tLVpWMU9BYmxQWE44OHRLRi1DbjI4R04zaVNwM25kNy1IeUs5XzBGbFdYcnc5LXNZRF8xaXk2S1BHTGt3YVpYMEdJ?oc=5","date":"2026-03-04","type":"pipeline","source":"Yahoo Finance","summary":"How The Alector (ALEC) Story Is Shifting As Analyst Targets And Sector Views Evolve - Yahoo Finance","headline":"How The Alector (ALEC) Story Is Shifting As Analyst Targets And Sector Views Evolve","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-22","type":"earnings","source":"simplywall.st","summary":"There's No Escaping Alector, Inc.'s (NASDAQ:ALEC) Muted Revenues Despite A 32% Share Price Rise - simplywall.st","headline":"There's No Escaping Alector, Inc.'s (NASDAQ:ALEC) Muted Revenues Despite A 32% Share Price Rise","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQSi1QaWJVVWJyR0U1akgxamhjYzAzZFVoWERmb0xWM2dCUjVvV29JamF4TEh6bUZ6dVdzb0VOQ3pGbDN4MjRGcGlPRUlaNWRrcXNFN0pjR201R01qcmJ1SGRqeGZDVXFiY2c0MmgzWnIxQ3pYNkMyUHNkQml5eXVtT1gxTVk1WmVKTFNFYTBvNDE4dVAxd1ZjaE45TTlzWmY0VXlTMl9ocFVHR2pPRGNXN3QtWWs?oc=5","date":"2026-01-19","type":"pipeline","source":"BioSpace","summary":"4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment - BioSpace","headline":"4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQNWlnbmFLS0JQdlhMYkswQXYyZFZXeHh0RXZIalkybFR3NGYtdDZKYlgzOG5LeFJGNXRjYjRUdUhCVVVaNUVydmh2WXFEakpWMTBodFN3anRFQjNMRDQwUEhhQTk5STBDSFVsVFFjaDJpck1USmxlUzJtNV9lSmhuVUVwcmxVZkRlaDVENG9WWW5sUQ?oc=5","date":"2025-10-23","type":"deal","source":"pharmaphorum","summary":"Alector ditches GSK-partnered dementia drug and cuts staff - pharmaphorum","headline":"Alector ditches GSK-partnered dementia drug and cuts staff","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQRkhRT081WUJMa0FSa2JLakNJSjBDX2todVJfUmJYVDRobU5BVlZoVzZCNTFwdE9nREhja3k4ZmV1eVltWFdBM3VCVDJkV0t5M1JjaWV1VWljbkp6SHJQUEZacUQ4UDNqOHQ0X0xnSTkyTlh3RHhzTFJCUjNpUkxhYzAxMWc4SzJ1dmxPWDZvNDJoMVQ2Q04tWHNoSVUyWWlf?oc=5","date":"2025-10-23","type":"trial","source":"The Pharma Letter","summary":"Alector slashes workforce after dementia trial failure - The Pharma Letter","headline":"Alector slashes workforce after dementia trial failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQTXJEOXBDOG96WlpBcWVQS2pMd2hqelJFcVRJZ3kxWHEyNDdMMWYzUWNMWjJKanRQcUljOUZRQmVTZF9Nc2QtdC1yWEh3NHljNWJYSEF6dTJEdmtLeUJVX1VhWU9BVklsSTFuLW8xUmRBUDFmSTJXWVRBTnJuXzBlcGFia19NZXNlU3RlcFFJMl9tajAweF8xdnVsU3k5VGpDUFRnTmNZN1RkWUt1UXBUQy12Wk55VHZPelplZw?oc=5","date":"2025-10-22","type":"trial","source":"Fierce Biotech","summary":"Alector halves staff after GSK-partnered antibody flops phase 3 dementia trial - Fierce Biotech","headline":"Alector halves staff after GSK-partnered antibody flops phase 3 dementia trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOdVUxRHFCSHVqZUlwWS1FRGgydmc2dHNTdk5BNG5DNUNFR1ptQjAwS2h1YzhDWWFhXzRJajBDUFE2NFdtVkdoVjNtVW1qZ0JmMjdxVmx1U0o0RExiZjZJZldzLU1JN2ZrbVhvSDhMMUxRQTh5ZndmdjUtcGN1Y2tNODlZQ29XVU9jVXpiLUNJbzA0VGNPSWJIcmZTMTczWUFtWk9jZU1nZw?oc=5","date":"2025-10-22","type":"trial","source":"BioPharma Dive","summary":"Alector dementia drug, partnered with GSK, fails in key study - BioPharma Dive","headline":"Alector dementia drug, partnered with GSK, fails in key study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQSDM3am5OU2MxNmhCM0NBb016Qy1aMHJQZHNDQTVVRlEycS1mSHBJQ2VUWmJBclJvQmp4cnhLSDF5WUFOVTdfRFdoazdZT09SZnV5WTMyck80SmVIekl3NExDa0JoZnFmWFdBb05zU3EyTUpwalo1NGoxRDBmdzBSamU2MW9OZi1lUjZrY2J2NTZsc2VteWQ2OEN0LUhPbUE1Z3NwblY5QQ?oc=5","date":"2025-10-22","type":"trial","source":"BioWorld News","summary":"Alector stock and staff halved after phase III fail in dementia - BioWorld News","headline":"Alector stock and staff halved after phase III fail in dementia","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1kNktCYkFRMDgxUUR6MV9iVFNaVGRVQ29fNWJqR0tHQWY4bm5WTzQ1QzhVNWlsV3U5SkZubUVkdjBQcVR3bDFjeUNLajRKRFBpTWQzeEpXQ2xtTmlGUExaMVBNZlY0YXFzb0VlSmNGRVhfdw?oc=5","date":"2025-10-22","type":"pipeline","source":"StocksToTrade","summary":"Alector’s Turbulent Ride: Is Recovery Possible? - StocksToTrade","headline":"Alector’s Turbulent Ride: Is Recovery Possible?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOOFhQeWJKRnMzZTNjbS1lNUJqakotTWdIVDhic2dFNWRWdGFuVjBjcWloUWNYVHFYUjF6YzZ1WVJDdUk0eEpKR3dRdVVvNTM1Tm1ObGNEbzI1eFhQMjcySjFPYVM0QjRfeldnWEozbDRkUjRhX2JHM21sbFZJczdXVmd5XzhVZGNUQUdtdTB0Ym0xRmNhNXg5RkpScDRBSzR0cHcya2VEXzd3TjQ?oc=5","date":"2025-10-22","type":"trial","source":"Bloomberg.com","summary":"GSK, Alector Drug Fails to Slow Type of Dementia in Trial - Bloomberg.com","headline":"GSK, Alector Drug Fails to Slow Type of Dementia in Trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxORWxPajhweGZmR2lEd2RFa2xaTk5sT3ZoX193TzY0WDFUNWF2cllHaGdxRFNEQl9id2dJRFNVSUpXa2NTOW43QTBvY3JkYm5lajdLaEdKUHVpdE1pNjg3eTdQVlpNa0xBZDdvdjJVREE5d1FuZ0dTdENPbHBDeDh6MXJyejV6NF9z?oc=5","date":"2025-10-21","type":"trial","source":"statnews.com","summary":"Alector’s dementia drug fails to slow patient decline in late-stage trial - statnews.com","headline":"Alector’s dementia drug fails to slow patient decline in late-stage trial","sentiment":"negative"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}